This indicates that HER3 overexpression, even after the pronounced increase in HER3 levels upon treatment with MET inhibitors or siRNA, is insufficient to compensate for the blocking of MET-dependent pathways in tumor cells that do not endogenously express heregulin. Here, ERBB3 is linked to neoplasm.